Consolidated Statements of Equity - USD ($) shares in Thousands, $ in Thousands	Total	Total Caladrius Biosciences, Inc. Stockholders' Equity	Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (shares) at Dec. 31, 2019			10	10,529
Beginning Balance at Dec. 31, 2019	$ 20,553	$ 20,816	$ 0	$ 11	$ 438,911	$ 2	$ (417,400)	$ (708)	$ (263)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(3,986)	(3,990)					(3,990)		4
Unrealized loss on marketable securities	(2)	(2)				(2)
Share-based compensation (in shares)				110
Share-based compensation	419	419			419
Ending Balance (shares) at Mar. 31, 2020			10	10,639
Ending Balance at Mar. 31, 2020	16,984	17,243	$ 0	$ 11	439,330	0	(421,390)	(708)	(259)
Beginning Balance (shares) at Dec. 31, 2020			10	19,389
Beginning Balance at Dec. 31, 2020	32,242	32,496	$ 0	$ 19	458,748	(13)	(425,550)	(708)	(254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,063)	(8,063)					(8,063)		0
Unrealized loss on marketable securities	(59)	(59)				(59)
Share-based compensation (in shares)				273
Share-based compensation	413	413			413
Net proceeds from issuance of common stock and warrants (in shares)				39,841
Net proceeds from issuance of common stock and warrants	85,457	85,457		$ 41	85,416
Proceeds from option exercises (in shares)				7
Proceeds from option exercises	24	24			24
Ending Balance (shares) at Mar. 31, 2021			10	59,510
Ending Balance at Mar. 31, 2021	$ 110,014	$ 110,268	$ 0	$ 60	$ 544,601	$ (72)	$ (433,613)	$ (708)	$ (254)